Hepatocellular carcinoma after direct‐acting antivirals for hepatitis C is associated with KIR‐HLA types predicting weak NK cell‐mediated immunity
European Journal of Immunology · 2024
DOI: 10.1002/eji.202350678 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2024. Verfasst von James C Ryan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Killer Cells, Natural, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, Department of Veterans Affairs Merit, CSRD VA.
Abstract (Originalsprache)
Background and aims Second‐generation direct‐acting antivirals (2G DAA) to cure HCV have led to dramatic clinical improvements. HCV‐associated hepatocellular carcinoma (HCC), however, remains common. Impaired immune tumor surveillance may play a role in HCC development. Our cohort evaluated the effects of innate immune types and clinical variables on outcomes including HCC.
Methods
Participants underwent full HLA class I/KIR typing and long‐term HCV follow‐up.
Results
A total of 353 HCV+ participants were followed for a mean of 7 years. Cirrhosis: 25% at baseline, developed in 12% during follow‐up. 158 participants received 2G DAA therapy. HCC developed without HCV therapy in 20 subjects, 24 HCC after HCV therapy, and 10 of these after 2G DAA. Two predictors of HCC among 2G DAA‐treated patients: cirrhosis (OR, 10.0, p = 0.002) and HLA/KIR profiles predicting weak natural killer (NK) cell‐mediated immunity (NK cell complementation groups 6, 9, 11, 12, OR of 5.1, p = 0.02). Without 2G DAA therapy: cirrhosis was the main clinical predictor of HCC (OR, 30.8, p < 0.0001), and weak NK‐cell‐mediated immunity did not predict HCC.
Conclusion
Cirrhosis is the main risk state predisposing to HCC, but weak NK‐cell‐mediated immunity may predispose to post‐2G DAA HCC more than intermediate or strong NK‐cell‐mediated immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
- Division of Gastroenterology, University of California, San Francisco, California, USA.
- Department of Medicine, University of California, San Francisco, California, USA.
- Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Department of Microbiology and Immunology, University of California, San Francisco, California, USA.
ORCID-Profile: Alexander Monto
Förderung
- NIDDK NIH HHS
- Department of Veterans Affairs Merit
- CSRD VA
- NIAID NIH HHS
- Dr. Monto and the National Institute of Allergy and Infectious Diseases (NIAID) R01
Zitieren
APA
Ryan, J. C., Haight, C., Niemi, E. C., Grab, J. D., Dodge, J. L., Lanier, L. L., & Monto, A. (2024). Hepatocellular carcinoma after direct‐acting antivirals for hepatitis C is associated with KIR‐HLA types predicting weak NK cell‐mediated immunity. European Journal of Immunology. https://doi.org/10.1002/eji.202350678
Vancouver
Ryan JC, Haight C, Niemi EC, Grab JD, Dodge JL, Lanier LL, et al. Hepatocellular carcinoma after direct‐acting antivirals for hepatitis C is associated with KIR‐HLA types predicting weak NK cell‐mediated immunity. European Journal of Immunology. 2024. doi:10.1002/eji.202350678
BibTeX
@article{Ryan2024,
author = {Ryan, James C and Haight, Christina and Niemi, Erene C and Grab, Joshua D and Dodge, Jennifer L and Lanier, Lewis L and Monto, Alexander},
title = {Hepatocellular carcinoma after direct‐acting antivirals for hepatitis C is associated with KIR‐HLA types predicting weak NK cell‐mediated immunity},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202350678}
}
EUVIMED